CA2180535C - A method for treatment of psoriasis, by omeprazole or related compounds - Google Patents
A method for treatment of psoriasis, by omeprazole or related compounds Download PDFInfo
- Publication number
- CA2180535C CA2180535C CA002180535A CA2180535A CA2180535C CA 2180535 C CA2180535 C CA 2180535C CA 002180535 A CA002180535 A CA 002180535A CA 2180535 A CA2180535 A CA 2180535A CA 2180535 C CA2180535 C CA 2180535C
- Authority
- CA
- Canada
- Prior art keywords
- omeprazole
- psoriasis
- treatment
- administration
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960000381 omeprazole Drugs 0.000 title claims abstract description 45
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 title abstract description 10
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 150000001447 alkali salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006872 improvement Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 4
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 3
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
- 229960005019 pantoprazole Drugs 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CUDVHEFYRIWYQD-UHFFFAOYSA-N E-3810 free base Chemical compound C=1C=C2C(C(=O)NC)=CC=CC2=CC=1OC(C1=CC=2OC)=CC=NC1=CC=2OCC1(N)CC1 CUDVHEFYRIWYQD-UHFFFAOYSA-N 0.000 description 2
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- IPAJARTUAXFVLF-UHFFFAOYSA-N sodium;9-(1h-benzimidazol-2-ylsulfinyl)-4-methoxy-2,5,6,7,8,9-hexahydrocyclohepta[b]pyridin-1-ide Chemical compound [Na+].COC1=CC[N-]C2=C1CCCCC2S(=O)C1=NC2=CC=CC=C2N1 IPAJARTUAXFVLF-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
- 206010036186 Porphyria non-acute Diseases 0.000 description 1
- 206010065874 Psoriatic conditions Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A method for treatment of psoriasis, characterized in administration of a th erapeutically effective dose of omeprazole or related compounds.
Description
218053 5 .1 A method for treatment of psoriasis, by omeprazole or related compounds.
Field of invention The present invention relates to a novel method of treating psoriasis.
Background of the invention Psoriasis is a primary disease of the skin characterised by well-demarcated, inflammatory papules and plaques, which are typically covered by thickened scales.
It is a disease of increased proliferation of epidermal cells, the precise cause of which is unknown.
The incidence of psoriasis in e.g. the US is about 2%. About 3% of whites and 1%
of blacks are affected.
Therapeutic efforts in psoriasis are aimed at decreasing the proliferative rate of the epidermis either by direct action on cell division, or through agents that reduce the inflammatory response or vascular permeability. For patients with localised, limited psoriasis, topical administration of calcipotriol(D-vitamin derivative), dithranol or corticosteroids are the most convenient outpatient therapy. For patients with more extensive disease topical treatment followed by eradication with UV light may be necessary.
For patients with extensive disease a systemic antinutotic agent, such as methotrexate, can be used.
Extensive psoriasis can also be treated with photochemotherapy. In this regimen, orally administered, 8-methoxypsoralen produces photosensitization, which is followed by exposure to ultraviolet A (PUVA, 320 nm).
WO 95118612 ~ ~ PCT/SE94100006 The retinoids, particularly eretrinate, either alone or in combination with PWA, are also effective treatment for psoriasis. Furthermore, during acute attacks of pustular psoriasis, systemic steroids have been the therapy of choice.
S In view of postulated immunologic mechanisms it is interesting that cyclosporin A
has been shown to be an effective treatment. Considering the risk for complications, such treatment should, however, be reserved for patients with recalcitrant, debilitating psoriasis when the benefit outweighs the potential risk of complications.
As will be clear from the above, there is a need for new, alternative and improved methods for treating psoriasis. The present invention provides a novel method for the treatment of psoriasis.
Detailed descriution of the invention It has been found according to the invention that administration of omeprazole to patients affected by psoriasis results in disappearance of or great improvement of the symptoms of psoriasis. This applies to all manifestations of psoriasis.
Omeprazole is a pharmaceutical agent having the formula \ I Ii ~ OCH3 N CH2-S~ I /
N
H
and is used in therapy for treatment of gastric acid related diseases, such as gastric ulcer.
Omeprazole can be administered orally, rectally or parenterally in neutral form or in the form of a basic salt, such as the Mg2+, Ca2+, Na+, or K+ salts, preferably the Mg2+ or Na+ salts. While the effect on the symptoms of psoriasis have been established in patients who have taken omeprazole by the oral route, it is believed that the effect of omeprazole on psoriasis is a ~ systemic effect which is not dependent on what mode of administration that is used, and that accordingly the healing effect on psoriasis will be seen also with other routes of administration such as rectal or parenteral administration.
Omeprazole can also be used in the form of a substantially pure enantiomer, or a salt thereof such as the salts mentioned above.
The commercially available pharmaceutical formulations of omeprazole will normally be used also for the use of omeprazole for treating psoriasis.
Examples of such commercially available formulations are:
- pellets of omeprazole, packaged in capsules - tablet containing omeprazole as active ingredient - solutions for parenteral administration, comprising e.g. the sodium salt of omeprazole as active ingredient.
Being a labile compound with poor storage stability at neutral or acid pH, omeprazole formulations must be produced with great care. Examples of ways of producing stable fomlulations are given in e.g. EP-A-247,983.
The dose of omeprazole to be administered at treatment of psoriasis will vary depending on factors such as the severity of the disease and the status of the patient. The dosage range at oral, rectal as well as i.v. administration may be in the interval from 1 to 100 mg per day. Normally, an amount of from 10 to 40 mg of omeprazole a day is envisaged at oral administration. A particularly suitable dosage may be in the range of 10-20 mg omeprazole per day.
Other compounds which can be used in the treatment of psoriasis in the same manner as omeprazole are the following:
H 259/31 N ~ F
-S
N
I
H
OC f H
C H~ S--~
H2~-O-CH2CH3 O
WO 95/18612 ~ ~ ~ PCT/SE94/00006 O N
Lansoprazole O I) N
i H
Pantoprazole O i1 S
N
i H
E-sago ~ ~ N
H
~1~053 5 CHg CH3 N
N s TU-199 N N ~OCZi3 H
Field of invention The present invention relates to a novel method of treating psoriasis.
Background of the invention Psoriasis is a primary disease of the skin characterised by well-demarcated, inflammatory papules and plaques, which are typically covered by thickened scales.
It is a disease of increased proliferation of epidermal cells, the precise cause of which is unknown.
The incidence of psoriasis in e.g. the US is about 2%. About 3% of whites and 1%
of blacks are affected.
Therapeutic efforts in psoriasis are aimed at decreasing the proliferative rate of the epidermis either by direct action on cell division, or through agents that reduce the inflammatory response or vascular permeability. For patients with localised, limited psoriasis, topical administration of calcipotriol(D-vitamin derivative), dithranol or corticosteroids are the most convenient outpatient therapy. For patients with more extensive disease topical treatment followed by eradication with UV light may be necessary.
For patients with extensive disease a systemic antinutotic agent, such as methotrexate, can be used.
Extensive psoriasis can also be treated with photochemotherapy. In this regimen, orally administered, 8-methoxypsoralen produces photosensitization, which is followed by exposure to ultraviolet A (PUVA, 320 nm).
WO 95118612 ~ ~ PCT/SE94100006 The retinoids, particularly eretrinate, either alone or in combination with PWA, are also effective treatment for psoriasis. Furthermore, during acute attacks of pustular psoriasis, systemic steroids have been the therapy of choice.
S In view of postulated immunologic mechanisms it is interesting that cyclosporin A
has been shown to be an effective treatment. Considering the risk for complications, such treatment should, however, be reserved for patients with recalcitrant, debilitating psoriasis when the benefit outweighs the potential risk of complications.
As will be clear from the above, there is a need for new, alternative and improved methods for treating psoriasis. The present invention provides a novel method for the treatment of psoriasis.
Detailed descriution of the invention It has been found according to the invention that administration of omeprazole to patients affected by psoriasis results in disappearance of or great improvement of the symptoms of psoriasis. This applies to all manifestations of psoriasis.
Omeprazole is a pharmaceutical agent having the formula \ I Ii ~ OCH3 N CH2-S~ I /
N
H
and is used in therapy for treatment of gastric acid related diseases, such as gastric ulcer.
Omeprazole can be administered orally, rectally or parenterally in neutral form or in the form of a basic salt, such as the Mg2+, Ca2+, Na+, or K+ salts, preferably the Mg2+ or Na+ salts. While the effect on the symptoms of psoriasis have been established in patients who have taken omeprazole by the oral route, it is believed that the effect of omeprazole on psoriasis is a ~ systemic effect which is not dependent on what mode of administration that is used, and that accordingly the healing effect on psoriasis will be seen also with other routes of administration such as rectal or parenteral administration.
Omeprazole can also be used in the form of a substantially pure enantiomer, or a salt thereof such as the salts mentioned above.
The commercially available pharmaceutical formulations of omeprazole will normally be used also for the use of omeprazole for treating psoriasis.
Examples of such commercially available formulations are:
- pellets of omeprazole, packaged in capsules - tablet containing omeprazole as active ingredient - solutions for parenteral administration, comprising e.g. the sodium salt of omeprazole as active ingredient.
Being a labile compound with poor storage stability at neutral or acid pH, omeprazole formulations must be produced with great care. Examples of ways of producing stable fomlulations are given in e.g. EP-A-247,983.
The dose of omeprazole to be administered at treatment of psoriasis will vary depending on factors such as the severity of the disease and the status of the patient. The dosage range at oral, rectal as well as i.v. administration may be in the interval from 1 to 100 mg per day. Normally, an amount of from 10 to 40 mg of omeprazole a day is envisaged at oral administration. A particularly suitable dosage may be in the range of 10-20 mg omeprazole per day.
Other compounds which can be used in the treatment of psoriasis in the same manner as omeprazole are the following:
H 259/31 N ~ F
-S
N
I
H
OC f H
C H~ S--~
H2~-O-CH2CH3 O
WO 95/18612 ~ ~ ~ PCT/SE94/00006 O N
Lansoprazole O I) N
i H
Pantoprazole O i1 S
N
i H
E-sago ~ ~ N
H
~1~053 5 CHg CH3 N
N s TU-199 N N ~OCZi3 H
N -_ J~N
N
1'Y -11345 H
Where applicable, a compound listed above may be used in racemic form or in the form of a substantially pure enantiomer. The compounds listed may be used in the same manner as described above for omeprazole, 1.e. be administrated orally, rectally as well as parenterally.
Parenteral administration is feasible provided that the compound is water soluble. Suitable compounds for parenteral administration are H 259/31, H 287/23, lansoprazole, pantoprazole, E-3810, TU-199 and TY-11345. Dosages to be administered can be in the same ranges as given above for omeprazole.
The present invention extends to a commercial package containing, as active ingredient a compound selected from the group consisting of omeprazole, H 259/31, H 287/23, H 326/07, lansoprazole, pantoprazole, E-3810, TU-199 and TY-11345, or a pharmaceutically acceptable salt thereof, together with instructions for its use for the treatment of ~1~0 - 6a -psoriasis.
The invention is further exemplified by the following case studies. During oral treatment with omeprazole for acid related diseases, evidence has accumulated that omeprazole may be beneficial for treatment of psoriasis. Some examples are presented below:
A
WO 95/18612 ~ ~ ~ ~ ~ PCT/SE94/00006 Case 1 - 70-year-old woman A 70 year old woman suffered since 53 years from typical chronic psoriasis vulgaris with main areas at both wrists as well as on her back. Treatment was, on basis of advice from her doctor, carried out with different gluco corticosteroids containing ointments as well as with salicyl-vaselin. However, the chronic state not changed.
Because of reflux esophagitis, degree III, the patient was treated since two years with omeprazole, once daily, 40 mg, evenings. After 3 weeks the patient noted for the first time the start of an improvement of her psoriasis. After 2 months, a clear improvement of the skin areas was established, an improvement which 2 years afterwards still was present. Already since the beginning of the improvement the patient used no external medicaments any longer.
Case 2 - 70-year-old man Simultaneous disease: porphyria cutanea tarda. Widespread psoriasis in his whole life, partly controlled with topical treatment and PUVA treatment.
Because of acid-related disease treatment with ranitidin was initiated and due to lack of efficacy the treatment was, after a few months, changed to omeprazole.
During one month's treatment with omeprazole the psoriatic condition improved considerably, but flared up again when the treatment was changed back to ranitidin.
The condition improved again when omeprazole was re-instituted and the patient is currently under treatment with omeprazole for his psoriasis.
Case 3 - A 70-year-old man with omeprazole since many years. Also father and sister have had psoriasis.
The condition has been treated topically, but has never been completely controlled, especially not in the hair bottom.
When treatment with omeprazole was started because of a bleeding ulcer the psoriatic lesions healed completely, including the changes in the hair bottom, which was noted spontaneously by the barber. The psoriatic lesions returned when the omeprazole treatment was stopped.
Case 4 - A 60-year-old lady with long-standing history of psoriasis. Whilst on omeprazole over a 3 month period there was a total and complete eradication of her psoriasis not only of the skin but of the finger nails. When omeprazole was stopped the condition started to recur.
Case 5 - A lady, age not known who has been treated for severe psoriasis for some years. She has needed systemic treatment at times but has never really been clear of skin lesions. When treatment with omeprazole was started because of a gastric ulceration, her psoriasis started to clear up over a S-week period.
N
1'Y -11345 H
Where applicable, a compound listed above may be used in racemic form or in the form of a substantially pure enantiomer. The compounds listed may be used in the same manner as described above for omeprazole, 1.e. be administrated orally, rectally as well as parenterally.
Parenteral administration is feasible provided that the compound is water soluble. Suitable compounds for parenteral administration are H 259/31, H 287/23, lansoprazole, pantoprazole, E-3810, TU-199 and TY-11345. Dosages to be administered can be in the same ranges as given above for omeprazole.
The present invention extends to a commercial package containing, as active ingredient a compound selected from the group consisting of omeprazole, H 259/31, H 287/23, H 326/07, lansoprazole, pantoprazole, E-3810, TU-199 and TY-11345, or a pharmaceutically acceptable salt thereof, together with instructions for its use for the treatment of ~1~0 - 6a -psoriasis.
The invention is further exemplified by the following case studies. During oral treatment with omeprazole for acid related diseases, evidence has accumulated that omeprazole may be beneficial for treatment of psoriasis. Some examples are presented below:
A
WO 95/18612 ~ ~ ~ ~ ~ PCT/SE94/00006 Case 1 - 70-year-old woman A 70 year old woman suffered since 53 years from typical chronic psoriasis vulgaris with main areas at both wrists as well as on her back. Treatment was, on basis of advice from her doctor, carried out with different gluco corticosteroids containing ointments as well as with salicyl-vaselin. However, the chronic state not changed.
Because of reflux esophagitis, degree III, the patient was treated since two years with omeprazole, once daily, 40 mg, evenings. After 3 weeks the patient noted for the first time the start of an improvement of her psoriasis. After 2 months, a clear improvement of the skin areas was established, an improvement which 2 years afterwards still was present. Already since the beginning of the improvement the patient used no external medicaments any longer.
Case 2 - 70-year-old man Simultaneous disease: porphyria cutanea tarda. Widespread psoriasis in his whole life, partly controlled with topical treatment and PUVA treatment.
Because of acid-related disease treatment with ranitidin was initiated and due to lack of efficacy the treatment was, after a few months, changed to omeprazole.
During one month's treatment with omeprazole the psoriatic condition improved considerably, but flared up again when the treatment was changed back to ranitidin.
The condition improved again when omeprazole was re-instituted and the patient is currently under treatment with omeprazole for his psoriasis.
Case 3 - A 70-year-old man with omeprazole since many years. Also father and sister have had psoriasis.
The condition has been treated topically, but has never been completely controlled, especially not in the hair bottom.
When treatment with omeprazole was started because of a bleeding ulcer the psoriatic lesions healed completely, including the changes in the hair bottom, which was noted spontaneously by the barber. The psoriatic lesions returned when the omeprazole treatment was stopped.
Case 4 - A 60-year-old lady with long-standing history of psoriasis. Whilst on omeprazole over a 3 month period there was a total and complete eradication of her psoriasis not only of the skin but of the finger nails. When omeprazole was stopped the condition started to recur.
Case 5 - A lady, age not known who has been treated for severe psoriasis for some years. She has needed systemic treatment at times but has never really been clear of skin lesions. When treatment with omeprazole was started because of a gastric ulceration, her psoriasis started to clear up over a S-week period.
Claims (21)
1. Use of a therapeutically effective dose of omeprazole or a pharmaceutically acceptable salt thereof, for the treatment of psoriasis.
2. Use according to claim 1 for oral administration.
3. Use according to claim 1 for parenteral administration.
4. Use according to claim 1 for rectal administration.
5. Use according to any one of claims 1 to 4 wherein omeprazole is in neutral form.
6. Use according to any one of claims 1 to 4 wherein omeprazole is in the form of a basic salt.
7. Use according to claim 6, wherein the basic salt is a magnesium or sodium salt.
8. Use according to any one of claims 1 to 7 for administration in a dose of from 1 to 100 mg per day.
9. Use according to claim 8 for administration in a dose of from 10 to 40 mg per day.
10. A pharmaceutical composition for use in treatment of psoriasis comprising a therapeutically effective dose of omeprazole or a pharmaceutically acceptable salt thereof, together with a suitable diluent or carrier.
11. A composition according to claim 10 wherein omeprazole is in neutral form.
12. A composition according to claim 10 wherein omeprazole is in the form of a basic salt.
13. A composition according to claim 12 wherein the basic salt is a magnesium or sodium salt.
14. A composition according to any one of claims 10 to 13, which composition is in a form for oral administration.
15. A composition according to any one of claims 10 to 13, which composition is in a form for parenteral administration.
16. A composition according to any one of claims 10 to 13, which composition is in a form for rectal administration.
17. A composition according to any one of claims 10 to 16, which is in unit dosage form and contains from 1 to 100 mg of omeprazole or a pharmaceutically acceptable salt thereof.
18. A composition according to claim 17 which contains from 10 to 40 mg of omeprazole or a pharmaceutically acceptable salt thereof.
19. A process for the preparation of a pharmaceutical composition for the treatment of psoriasis, which comprises admixing a therapeutically effective dose of omeprazole, or a pharmaceutically acceptable salt thereof, with a suitable diluent or carrier.
20. A commercial package containing, as active ingredient, a therapeutically effective dose of omeprazole, or a pharmaceutically acceptable salt thereof, together with instructions for its use for the treatment of psoriasis.
21. A commercial package comprising a composition according to any one of claims 10 to 18, together with instructions for its use for the treatment of psoriasis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE1994/000006 WO1995018612A1 (en) | 1994-01-05 | 1994-01-05 | A method for treatment of psoriasis, by omeprazole or related compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2180535A1 CA2180535A1 (en) | 1995-07-13 |
| CA2180535C true CA2180535C (en) | 2004-03-23 |
Family
ID=20392490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002180535A Expired - Lifetime CA2180535C (en) | 1994-01-05 | 1994-01-05 | A method for treatment of psoriasis, by omeprazole or related compounds |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5714505A (en) |
| CA (1) | CA2180535C (en) |
| WO (1) | WO1995018612A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| AU742620B2 (en) * | 1998-01-30 | 2002-01-10 | Sepracor, Inc. | R-lansoprazole compositions and methods |
| AU3967399A (en) * | 1998-04-30 | 1999-11-16 | Sepracor, Inc. | S-rabeprazole compositions and methods |
| CA2329925A1 (en) * | 1998-05-05 | 1999-11-11 | Sepracor Inc. | Desmethylpantoprazole compositions and methods |
| IL142703A (en) * | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
| UA72748C2 (en) | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
| US20040224989A1 (en) * | 1999-01-29 | 2004-11-11 | Barberich Timothy J. | S-lansoprazole compositions and methods |
| US6174902B1 (en) | 1999-04-28 | 2001-01-16 | Sepracor Inc. | R-rabeprazole compositions and methods |
| US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| WO2001066117A1 (en) * | 2000-03-09 | 2001-09-13 | Ian Andrew Whitcroft | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
| EP1133987A1 (en) * | 2000-03-09 | 2001-09-19 | Ian Whitcroft | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
| MXPA04007169A (en) * | 2002-01-25 | 2004-10-29 | Santarus Inc | Transmucosal delivery of proton pump inhibitors. |
| FR2845916B1 (en) * | 2002-10-21 | 2006-07-07 | Negma Gild | PHARMACEUTICAL COMPOSITION ASSOCIATED WITH TENATOPRAZOLE AND HISTAMINE H2 RECEPTOR ANTAGONIST |
| EA200500673A1 (en) * | 2002-10-22 | 2005-12-29 | Рэнбакси Лабораториз Лимитед | AMORPHIC FORM OF SALT EZOMEPRAZOL, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION ON ITS BASIS |
| JP2006518751A (en) * | 2003-02-20 | 2006-08-17 | サンタラス インコーポレイティッド | Novel formulation for rapid and sustained suppression of gastric acid, omeprazole antacid complex-immediate release |
| WO2005007115A2 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2004257864A1 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2006043280A1 (en) * | 2004-10-19 | 2006-04-27 | Council Of Scientific And Industrial Research | Tenatoprazole salts and process of preparation thereof |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| DE102009018133A1 (en) * | 2009-04-15 | 2010-11-11 | Agon Pharma Gmbh | Pharmaceutical composition for the treatment of dermatological autoimmune diseases |
| US20100267959A1 (en) * | 2009-04-15 | 2010-10-21 | Glenmark Generics Limited | Process for the preparation of esomeprazole magnesium dihydrate |
| AU2013267022B2 (en) * | 2010-01-06 | 2016-04-21 | Elc Management Llc | Skin lightening compositions |
| AU2015200590B2 (en) * | 2010-01-06 | 2016-05-05 | Elc Management Llc | Skin lightening compositions |
| US8722026B2 (en) * | 2010-01-06 | 2014-05-13 | Elc Management, Llc | Skin lightening compositions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
-
1994
- 1994-01-05 US US08/666,504 patent/US5714505A/en not_active Expired - Fee Related
- 1994-01-05 WO PCT/SE1994/000006 patent/WO1995018612A1/en active Application Filing
- 1994-01-05 CA CA002180535A patent/CA2180535C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995018612A1 (en) | 1995-07-13 |
| CA2180535A1 (en) | 1995-07-13 |
| US5714505A (en) | 1998-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2180535C (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
| CA2328730C (en) | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein | |
| AU711482B2 (en) | Compositions for treatment of diabetic complications | |
| RU2292208C2 (en) | New combination of anti-histamine agents having no sedative action with compounds effecting to leukotrien action for rhinitis/conjunctivitis treatment | |
| EP2054051B1 (en) | Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis | |
| JPS5973520A (en) | Non-irritant aqueous eye disease therapy composition | |
| KR100275823B1 (en) | Anti-ischemic drugs | |
| JP2007534730A (en) | A therapeutic composition comprising at least one pyrrolobenzodiazepine derivative and fludarabine | |
| CA2155971A1 (en) | Method of treating damaged mucosal and epithelial tissues with misoprostol | |
| AU706660B2 (en) | Use of certain angiotensin II type I receptor antagonists for dyspeptic symptons in mammals including man | |
| US5886012A (en) | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers | |
| US20120122919A1 (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| DE60124560T2 (en) | TREATMENT OF ANGIOGENESE-RELATED DISEASES WITH BENZOYL PHENYL ACETIC DERIVATIVES | |
| AU3640999A (en) | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | |
| Katoh et al. | Solitary mastocytoma treated with tranilast | |
| US5980938A (en) | Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) | |
| US5556871A (en) | Method for treating epithelial precancerous lesions with topical inidazoles | |
| WO1999043308A2 (en) | Treating pulmonary hypertension through tenascin suppression and elastase inhibition | |
| US4751236A (en) | Method for treating genital herpes | |
| AU2002366975B2 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
| JPH0576925B2 (en) | ||
| Van der Rhee et al. | Treatment of psoriasis vulgaris with a low-dosage Ro 10-9359 (Tigason) orally combined with corticosteroids topically | |
| US5792798A (en) | Method for inhibiting plasminogen activator inhibitor 1 | |
| AU2006287805A1 (en) | Method of treating glaucoma | |
| EP0279787A1 (en) | Pharmaceutical compositions with synergistic antisecretory action for the healing of gastroduodenal ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20140106 |